Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

An update on gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 2019 Jul;19(7):655-670

Date

05/07/2019

Pubmed ID

31056978

DOI

10.1080/14712598.2019.1607837

Scopus ID

2-s2.0-85068638885 (requires institutional sign-in at Scopus site)   36 Citations

Abstract

INTRODUCTION: Gene therapies can be envisioned for many disorders where conventional therapies fall short. Lysosomal Storage Disorders (LSDs) are inherited, mostly monogenic, disorders resulting from deficient lysosomal enzyme or co-factor activity. Existing standard-of-care treatments for LSDs are expensive and can negatively impact quality-of-life. They also may not be sufficiently efficacious. LSDs are particularly amenable to gene therapy as modified cells can secrete functional enzyme that can also correct unmodified cells. Gene therapies may thus be able to provide sustained long-term correction for LSD patients.

AREAS COVERED: We highlight recent advances and discuss advantages/disadvantages of gene therapies with a focus on lentiviral and adeno-associated virus vectors currently in clinical trials for LSDs. We also mention promising strategies that are close to clinical testing. We emphasize protocols using ex vivo hematopoietic stem cell-directed gene therapy, systemic/liver-directed gene therapy, and brain-directed gene therapy. We also discuss next-generation gene therapy approaches and how they may address emerging challenges in the field.

EXPERT OPINION: Gene therapy is still in its infancy with respect to LSDs. However, efficacy and safety has been demonstrated in numerous pre-clinical studies, and promising clinical results suggest that gene therapy treatment for several LSDs is a real possibility.

Author List

Nagree MS, Scalia S, McKillop WM, Medin JA

Author

Jeffrey A. Medin PhD Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Animals
Brain
Cell- and Tissue-Based Therapy
Dependovirus
Genetic Therapy
Genetic Vectors
Hematopoietic Stem Cells
Humans
Liver
Lysosomal Storage Diseases